|Dr. Seth Lederman||Co-Founder, Pres, CEO & Chairman||632.5k||N/A||1958|
|Mr. Bradley Saenger CPA||CFO & Treasurer||405k||N/A||1974|
|Dr. Gregory M. Sullivan||Chief Medical Officer & Sec.||405k||N/A||1966|
|Mrs. Jessica Edgar Morris||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Ronald R. Notvest Ph.D., MBA||Exec. VP of Commercial Planning and Devel.||N/A||N/A||N/A|
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. has a research collaboration agreement with Massachusetts General Hospital to develop TNX-1500, a humanized monoclonal antibody that targets CD154 for the prevention and treatment of organ transplant rejection. The company was founded in 2007 and is based in New York, New York.
Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.